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in cancer patients, to evaluate whether they relate to each 
other and whether they can be correlated with prognosis and 
outcomes. For this purpose, our group recently demonstrat-
ed that plasmatic N-terminal pro-brain natriuretic peptide 
is capable of identifying breast cancer patients undergoing 
 chemotherapy at risk of cardiotoxicity, and that the same bio-
marker is capable of giving a prognosis regarding patient out-
comes (6). In the present study, we prospectively measured 
circulating NRG1 and Gal-3 in breast cancer patients before 
and after chemotherapy, to examine whether these biomark-
ers can be correlated with patient survival and consequently 
be used as additional indicators of patient outcomes.
Patients and methods
We performed a prospective study of 50 breast can-
cer patients, 25 of whom were HER2-negative and 25 
HER2- positive, undergoing adjuvant chemotherapy, and of 
25 healthy controls. Patients were enrolled on the basis of 
the following criteria: (a) they were undergoing treatment 
with anthracyclines, taxanes and trastuzumab; (b) had filled 
in a questionnaire for the evaluation of the functional valid-
ity of the Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS), with a score between 0 and 2; (c) had 
normal indices of liver (bilirubin <1.5 mg/dL) and renal func-
tion (creatinine <1.5 mg/dL).
The chemotherapy was based on HER2 expression: HER2-
negative patients underwent treatment with epirubicin 
(90 mg/m2 every 21 days) and cyclophosphamide (600 mg/m2 
every 21 days × 4 cycles) (EC) + paclitaxel (80 mg/m2 every 
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Introduction
Neuregulins (NRGs) are proteins of the epidermal growth 
factor (EGF) family that bind human epidermal growth fac-
tor receptor 2 (HER2), HER3 and HER4. These growth factors 
play an important role in the development and progression of 
many types of human cancer, in particular of breast tumors, 
acting as mitogenic factors (1, 2). NRGs are produced by mi-
crovascular endothelial cells and can influence the growth 
rate of malignant cells through paracrine stimulation (3).
Galectin 3 (Gal-3) is a member of the β-galactoside-
binding lectin family and is a pleiotropic protein involved in 
many biological processes such as cell adhesion, migration, 
growth and apoptosis (4). Gal-3 plays an important role in 
neoplastic progression and is highly expressed by triple- 
negative breast cancer, for which it has been proposed as a 
potential therapeutic target (5).
In recent years, studies have been undertaken to under-
stand the clinical significance of several circulating molecules 
ABSTRACT
Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis 
and outcome of breast cancer patients. Neuregulin-1 (NRG1) and galectin-3 (Gal-3) are proteins that are involved 
in breast cancer development and patient survival; therefore, we studied whether the serum concentration of 
these 2 proteins can be correlated to breast cancer progression.
Methods: Plasmatic NRG1 and Gal-3 were evaluated in 25 healthy controls and 50 breast cancer patients at 
baseline and at 3 and 6 months after treatment with anthracyclines and taxanes, with or without trastuzumab.
Results: NRG1 and Gal-3 were significantly more elevated in cancer patients than in healthy controls; further-
more, NRG1 and Gal-3 were significantly increased after chemotherapy and were predictive of mortality at 1 year.
Conclusions: Circulating NRG1 and Gal-3 can be additional biomarkers indicative of prognosis and outcomes for 
breast cancer patients.
Keywords: Breast cancer, Galectin-3, Mortality, Neuregulin-1, Prognosis
Accepted: March 13, 2017
Published online: 
Corresponding author:
Dr. Susanna Scarpa
Dipartimento Medicina Sperimentale
Università Sapienza
Viale Regina Elena 324
00161 Roma, Italy
susanna.scarpa@uniroma1.it
Neuregulin-1 and galectin-3 in breast cancere2 
© 2017 Wichtig Publishing
7 days × 12 cycles); HER2-positive patients underwent EC + 
paclitaxel + trastuzumab (8 mg/kg loading dose, followed 
by 6 mg/kg every 21 days) followed by trastuzumab alone 
(1 year total).
Plasma concentrations of NRG1, Gal-3, N-terminal pro-
brain natriuretic peptide (NT-ProBNP), I troponin (Tn I) and 
creatine kinase-myocardial and brain (CK-MB) were evalu-
ated before chemotherapy (T0), and NRG1 and Gal-3 also 
at 3 months (T1) and 6 months (T2) after treatment in can-
cer patients. In parallel, plasma from healthy controls was 
evaluated for NRG1 and Gal-3. Venous blood (5 mL) was 
drawn into a lithium heparin tube, and within 30 minutes, 
the sample was centrifuged at 3000 rpm for 10 minutes to 
obtain the plasma. The supernatant was then transferred to 
an Eppendorf tube and stored at -80°C until measurements 
were performed. The following kits were utilized to evaluate 
Gal-3: VIDAS (bioMérieux); NRG1:  Abcam® Human ELISA Kit 
ab100614; Tn-I: Roche Elecsys kit; CK-MB: Roche Elecsys kit; 
NT-ProBNP: Roche Diagnostic GmbH kit (Roche, Mannheim, 
Germany).
All patients provided informed consent, and the study 
was approved by the institutional ethics committee.
Statistical analysis
Statistical analysis was performed using R version 3.1.3 
(2015-03-09; Smooth Sidewalk; R Foundation for Statistical 
Computing). All data were first analyzed for normality of distri-
bution using the D’Agostino-Pearson test of normality. Continu-
ous variables were expressed as means ± standard deviation 
(SD), unless otherwise specified, and the appropriate para-
metric test (t-test) was used to assess the significance of any 
differences between the 2 groups. Categorical variables were 
displayed as frequencies and compared using the Fischer test. 
For time-course comparisons, 1-way ANOVA was used. The 
receiver operating characteristic (ROC) curve was applied to 
evaluate the ability of the biomarkers to predict death at 1 year 
(6). Multiple regression analysis with stepwise variable selec-
tion was applied to assess independent correlations with death 
at 1 year. All statistical tests were 2-tailed, and a p value <0.05 
was considered statistically significant.
Results
Our cohort was composed of 50 women with breast can-
cer (mean age 54 years, SD = 7.3) and 25 healthy controls 
(mean age 50 years, SD = 8.7); breast cancer patients were 
selected on the basis of HER2 expression: 25 negative and 25 
positive.
Plasmatic NRG1 and Gal-3 were initially evaluated at base-
line before chemotherapy (T0) and both were significantly 
higher in cancer patients than in healthy controls: NRG1 had a 
mean value of 1.95 ng/mL in cancer patients versus 0.52 ng/mL 
in controls (p<0.0001), Gal-3 had a mean value of 18.41 ng/mL 
in cancer patients and of 6.73 ng/mL in controls (p<0.0001) 
(Tab. I). A time course analysis of plasmatic NGR1 and Gal-3 was 
performed in cancer patients at 3 (T1) and 6 (T2) months af-
ter chemotherapy and showed that both NGR1 and Gal-3 were 
significantly (p<0.0001) increased at T1 and T2 in both groups 
of patients: HER2+ and HER2- (Tab. II). However, the values for 
either NGR1 or Gal-3 at T1 and T2 were similar, suggesting that 
the 2 molecules did not increase significantly at 6 months from 
treatment, as compared with the values for 3 months.
Comparing the HER2+ and HER2- groups, both NRG1 and 
Gal-3 were significantly (p<0.0001) higher in HER2- patients 
at every time of detection: T0, T1 and T2 (Tab. II).
To evaluate whether Gal-3 and NGR1 could be correlated 
with patient survival, their baseline plasmatic values were ana-
lyzed in a ROC curve for prediction of mortality at 1 year, to-
gether with the plasmatic values of NT-ProBNP, Tn-I and CK-MB, 
which we and other authors had previously demonstrated to 
be biomarkers of toxicity in breast cancer and, exclusively for 
NT-ProBNP, also a marker of prognosis (6, 7). We found that 
Gal-3 and NRG1, and also NT-ProBNP, but not Tn-I or CK-MB, 
were significantly correlated with the prediction of death at 
1 year (Tab. III). Finally, the same biomarkers were evaluated 
in a multiple regression analysis for mortality prediction at 
1 year and showed that baseline plasmatic Gal-3, body mass 
index (BMI) and HER2 expression were independent factors 
with respect to mortality, while CK-MB, NRG1, NT-ProBNP and 
TABLE I -  Comparison between cancer patients and healthy con-
trols for neuregulin-1 (NRG1) and galectin-3 (Gal-3) levels 
at baseline (T0)
Biomarker Cancer  
patients (n = 50)
Healthy con-
trols (n = 25)
p value
NRG1, ng/mL 1.955 (1.2) 0.52 (0.2) 0.0001
Gal-3, ng/mL 18.41 (5.8) 6.73 (1.6) <0.0001
Values are means and standard deviation (SD), or p values.
TABLE II - Time course in cancer patients and HER2 groups
Biomarker and HER2 status T0 T1 T2 p value
NRG1 (ng/mL), HER2- 2.93 (1.66) 3.54 (1.79) 3.94 (1.95) <0.0001
NRG1 (ng/mL), HER2+ 0.98 (0.71) 1.97 (0.63) 2.18 (0.70) <0.0001
Gal-3 (ng/mL), HER2- 22.19 (8.88) 23.61 (8.79) 24.03 (8.76) <0.0001
Gal-3 (ng/mL), HER2+ 14.63 (2.77) 15.88 (2.86) 15.97 (3.17) <0.0001
Neuregulin-1 (NRG1) and galectin-3 (Gal-3) measured at baseline (T0) and 3 months (T1) and 6 months of chemotherapy (T2) in HER2- and HER2+ cancer  
patients. Values are means and standard deviation (SD), or p values.
SD = standard deviation.
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Tn I were not independent factors with respect to mortality 
(Tab. IV).
Discussion
At present, therapy for breast cancer has reached a high 
level of quality, but it is necessary to be able to easily differ-
entiate patients who need to be more aggressively treated, 
and this objective will be achievable whenever a more pre-
cise characterization of each single tumor in terms of progno-
sis and progression becomes feasible. So it is important that 
the identification of novel plasmatic molecules be added to 
that of established markers for the prediction of response to 
therapy and progression or relapse of breast cancer patients 
(8, 9). For this purpose, we recently described the fact that 
plasmatic NT-ProBNP can be used as a biomarker for early 
diagnosis of chemotherapy-related cardiotoxicity in breast 
cancer, and that this marker can also be predictive of patient 
outcomes (6).
In the present work, we found that baseline plasmatic 
values of NRG1 and Gal-3 were higher in breast cancer pa-
tients than in healthy controls and that these values were 
higher in HER- than HER2+ tumors, suggesting that the ma-
lignancy itself causes a dysregulation of these 2 circulating 
proteins. Furthermore, the data described are suggestive of 
the value of these 2 markers as prognostic indicators, be-
cause HER- patients have a worst outcome compared with 
HER2+ patients.
Further, we demonstrated that Gal-3 and NRG1 increased 
after 3 and 6 months of chemotherapy and that both mark-
ers were significantly correlated with the prediction of death 
at 1 year in our cohort of breast cancer patients. These find-
ings are in accordance with a recent study that described in-
creased Gal-3 at least 2 years after anthracycline treatment in 
pediatric patients (10) and with another study that showed 
an important correlation between plasmatic Gal-3 enhance-
ment and toxicity in a cohort of 59 breast cancer survivors 
1 year after anthracycline treatment (11). Furthermore, Gal-3 
has been described as a promoter of metastasis in colon (12) 
and breast cancer (13).
Regarding neuregulins, their increased expression has 
been detected in several neoplasias, and their presence has 
been implicated in the development of resistance to treat-
ments that target HER receptors (14). The data that we report 
for NGR1 are in accordance with a recent study where this 
plasmatic molecule was proposed as a potential prognostic 
marker of chemotherapy-induced cardiotoxicity (15). Our re-
sults are also in line with a recent study in which a monoclo-
nal antibody that blocks NGR1-induced ErbB4 signaling was 
able to inhibit proliferation and tissue remodeling of breast 
cancer (16).
Despite the small size of our cohort and the requirement 
to validate the obtained results in a larger number of pa-
tients, we can speculate on the potential role of NRG1 and 
Gal-3 as additional parameters, which can be included in the 
larger panel of serum biomarkers utilized to better assess the 
prognosis and outcomes of breast cancer patients. The utili-
zation of these novel markers is directed toward improving 
the management of breast cancer patients through the iden-
tification of appropriate and specific tools capable of more 
accurately defining the outcomes of the neoplastic disease. 
We are now tracking our cohort of patients over the years, 
measuring plasmatic NRG1 and Gal-3 during their follow-up, 
to confirm and clarify the value of these parameters as prog-
nostic markers in breast cancer.
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